Vilon

Vilon is the dipeptide Lys-Glu, or KE. Three Russian clinical abstracts report adjunct use in type 1 diabetes or stage III colorectal cancer, but omit the denominators, allocation, exposure, comparator results, and quantitative group estimates needed to judge efficacy. Animal tumor findings also conflict.

synthetic Lys-Glu dipeptide

Sequence KE
Synthetic dipeptide
Three Russian clinical reports with incomplete methods and results
Diabetes reports measured coagulation and immune markers
Conflicting animal tumor findings

What is Vilon?

Vilon is Lys-Glu, a two-amino-acid peptide abbreviated KE. It is different from Thymalin extract, AED Cartalax, KED peptides, and other thymic peptide products.

Russian RCT-indexed report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2006. Article in Russian with English abstract.

The abstract describes type 1 diabetes during destabilization, reports abnormal coagulation and fibrinolysis markers, and claims adjunct Vilon reduced or eliminated markers described as chronic disseminated intravascular coagulation. PubMed indexes the paper as a randomized controlled trial, but the abstract reports no denominator, allocation method, comparator results, route, regimen, attrition, quantitative group estimates, or patient-centered outcome.

Participants / model: People of different ages with destabilized type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to generally accepted diabetes treatment; regimen not stated
Study design: Russian-language report indexed as randomized controlled trial, with core trial details absent from the English abstract

Read the original source

Has Vilon shown a clinical benefit?

The three cited Russian abstracts report favorable coagulation or immune markers in type 1 diabetes and preliminary outcomes in stage III colorectal cancer. The abstracts do not report the denominator, allocation, exposure, comparator results, attrition, or quantitative group estimates needed to establish a Vilon-specific benefit.

The indexed abstracts omit the methods and results needed to estimate treatment effects. Biomarker changes do not establish diabetes control, complications, survival, or quality of life.

Russian RCT-indexed report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2006. Article in Russian with English abstract.

The abstract describes type 1 diabetes during destabilization, reports abnormal coagulation and fibrinolysis markers, and claims adjunct Vilon reduced or eliminated markers described as chronic disseminated intravascular coagulation. PubMed indexes the paper as a randomized controlled trial, but the abstract reports no denominator, allocation method, comparator results, route, regimen, attrition, quantitative group estimates, or patient-centered outcome.

Participants / model: People of different ages with destabilized type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to generally accepted diabetes treatment; regimen not stated
Study design: Russian-language report indexed as randomized controlled trial, with core trial details absent from the English abstract

Read the original source

Russian clinical report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2007. Article in Russian with English abstract.

The abstract says Vilon added to complex therapy increased antithrombin III and protein C, stimulated fibrinolysis, changed lymphocyte and IgA markers, and in most cases reduced the insulin dose needed to stabilize carbohydrate metabolism. It states no denominator, allocation, comparator results, route, regimen, attrition, quantitative group estimates, glycemic outcome, or adverse-event method.

Participants / model: Elderly people with type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to complex therapy; regimen not stated
Study design: Russian-language clinical report with incomplete methods and no usable effect estimate

Read the original source

Russian controlled-trial-indexed report · preliminary claims

Clinical report

Iaskevich LS et al. Advances in Gerontology, 2005. Article in Russian with English abstract.

The abstract describes Vilon added to radical multimodal treatment for elderly patients with stage III rectal or colon cancer and makes preliminary claims about two-year survival, postoperative and later complications, recurrence, dissemination, and quality of life. PubMed indexes it as a clinical and controlled clinical trial, but the abstract gives no denominator, allocation, comparator results, route, regimen, attrition, effect estimates, uncertainty, or adverse-event data.

Participants / model: Elderly patients with stage III rectal or colon cancer; denominator not stated in the abstract
Treatment: Vilon added to surgery, radiotherapy, and chemotherapy; regimen not stated
Study design: Russian-language controlled-trial-indexed report with preliminary conclusions and insufficient methods or results

Read the original source

ClinicalTrials.gov · no relevant intervention trial

Trial registrations

ClinicalTrials.gov.

ClinicalTrials.gov lists no exact-name Vilon intervention study. Older Russian-language reports without matching registrations remain separate evidence.

Read the original source

Does Vilon prevent tumors?

Three rodent models reported favorable tumor outcomes, while a HER2/neu mouse experiment found earlier and more numerous mammary tumors. The conflicting models do not support a general anticancer conclusion.

Why do the animal studies conflict?

The models used different conditions and produced opposing tumor findings. Neither supplies a human benefit or a quantified human cancer risk.

Mouse tumors · earlier and multiple tumors reported

Animal carcinogenesis study

Anisimov VN et al. Bulletin of Experimental Biology and Medicine, 2001.

In HER2/neu transgenic mice, Vilon was associated with earlier tumor appearance and more multiple mammary tumors. The model cannot quantify human cancer risk; its direction was adverse.

Participants / model: HER2/neu transgenic mice
Treatment: Vilon
Study design: Animal carcinogenesis study

Read the original source

Animal tumors · favorable finding in another model

Animal study

Anisimov VN et al. Russian experimental oncology research.

A different animal experiment reported a favorable tumor-related finding after Vilon. Differences in model, timing, and endpoint prevent combining it into a general anticancer claim.

Participants / model: Experimental animal tumor model
Treatment: Vilon
Study design: Animal tumor study

Read the original source

Mouse tumors · earlier and multiple tumors reported

Animal carcinogenesis study

Anisimov VN et al. Bulletin of Experimental Biology and Medicine, 2001.

In HER2/neu transgenic mice, Vilon was associated with earlier tumor appearance and more multiple mammary tumors. The model cannot quantify human cancer risk; its direction was adverse.

Participants / model: HER2/neu transgenic mice
Treatment: Vilon
Study design: Animal carcinogenesis study

Read the original source

Animal tumors · favorable finding in another model

Animal study

Anisimov VN et al. Russian experimental oncology research.

A different animal experiment reported a favorable tumor-related finding after Vilon. Differences in model, timing, and endpoint prevent combining it into a general anticancer claim.

Participants / model: Experimental animal tumor model
Treatment: Vilon
Study design: Animal tumor study

Read the original source

What is known about safety?

The three human abstracts do not expose adverse-event denominators or collection methods. Repeated-use, immune, pregnancy, diabetes-treatment interaction, cancer-treatment interaction, and product-quality risks remain unknown, and the adverse mouse tumor result prevents a reassuring assessment of oncologic safety.

Russian RCT-indexed report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2006. Article in Russian with English abstract.

The abstract describes type 1 diabetes during destabilization, reports abnormal coagulation and fibrinolysis markers, and claims adjunct Vilon reduced or eliminated markers described as chronic disseminated intravascular coagulation. PubMed indexes the paper as a randomized controlled trial, but the abstract reports no denominator, allocation method, comparator results, route, regimen, attrition, quantitative group estimates, or patient-centered outcome.

Participants / model: People of different ages with destabilized type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to generally accepted diabetes treatment; regimen not stated
Study design: Russian-language report indexed as randomized controlled trial, with core trial details absent from the English abstract

Read the original source

Russian clinical report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2007. Article in Russian with English abstract.

The abstract says Vilon added to complex therapy increased antithrombin III and protein C, stimulated fibrinolysis, changed lymphocyte and IgA markers, and in most cases reduced the insulin dose needed to stabilize carbohydrate metabolism. It states no denominator, allocation, comparator results, route, regimen, attrition, quantitative group estimates, glycemic outcome, or adverse-event method.

Participants / model: Elderly people with type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to complex therapy; regimen not stated
Study design: Russian-language clinical report with incomplete methods and no usable effect estimate

Read the original source

Russian controlled-trial-indexed report · preliminary claims

Clinical report

Iaskevich LS et al. Advances in Gerontology, 2005. Article in Russian with English abstract.

The abstract describes Vilon added to radical multimodal treatment for elderly patients with stage III rectal or colon cancer and makes preliminary claims about two-year survival, postoperative and later complications, recurrence, dissemination, and quality of life. PubMed indexes it as a clinical and controlled clinical trial, but the abstract gives no denominator, allocation, comparator results, route, regimen, attrition, effect estimates, uncertainty, or adverse-event data.

Participants / model: Elderly patients with stage III rectal or colon cancer; denominator not stated in the abstract
Treatment: Vilon added to surgery, radiotherapy, and chemotherapy; regimen not stated
Study design: Russian-language controlled-trial-indexed report with preliminary conclusions and insufficient methods or results

Read the original source

Mouse tumors · earlier and multiple tumors reported

Animal carcinogenesis study

Anisimov VN et al. Bulletin of Experimental Biology and Medicine, 2001.

In HER2/neu transgenic mice, Vilon was associated with earlier tumor appearance and more multiple mammary tumors. The model cannot quantify human cancer risk; its direction was adverse.

Participants / model: HER2/neu transgenic mice
Treatment: Vilon
Study design: Animal carcinogenesis study

Read the original source

Is Vilon approved?

The cited US records contain no FDA-approved Vilon drug or registered intervention trial, and the cited sources include no current official Russian product label.

ClinicalTrials.gov · no relevant intervention trial

Trial registrations

ClinicalTrials.gov.

ClinicalTrials.gov lists no exact-name Vilon intervention study. Older Russian-language reports without matching registrations remain separate evidence.

Read the original source

Studies and sources

Russian RCT-indexed report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2006. Article in Russian with English abstract.

The abstract describes type 1 diabetes during destabilization, reports abnormal coagulation and fibrinolysis markers, and claims adjunct Vilon reduced or eliminated markers described as chronic disseminated intravascular coagulation. PubMed indexes the paper as a randomized controlled trial, but the abstract reports no denominator, allocation method, comparator results, route, regimen, attrition, quantitative group estimates, or patient-centered outcome.

Participants / model: People of different ages with destabilized type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to generally accepted diabetes treatment; regimen not stated
Study design: Russian-language report indexed as randomized controlled trial, with core trial details absent from the English abstract

Read the original source

Russian clinical report · denominator missing

Clinical report

Kuznik BI et al. Advances in Gerontology, 2007. Article in Russian with English abstract.

The abstract says Vilon added to complex therapy increased antithrombin III and protein C, stimulated fibrinolysis, changed lymphocyte and IgA markers, and in most cases reduced the insulin dose needed to stabilize carbohydrate metabolism. It states no denominator, allocation, comparator results, route, regimen, attrition, quantitative group estimates, glycemic outcome, or adverse-event method.

Participants / model: Elderly people with type 1 diabetes; denominator not stated in the abstract
Treatment: Vilon added to complex therapy; regimen not stated
Study design: Russian-language clinical report with incomplete methods and no usable effect estimate

Read the original source

Russian controlled-trial-indexed report · preliminary claims

Clinical report

Iaskevich LS et al. Advances in Gerontology, 2005. Article in Russian with English abstract.

The abstract describes Vilon added to radical multimodal treatment for elderly patients with stage III rectal or colon cancer and makes preliminary claims about two-year survival, postoperative and later complications, recurrence, dissemination, and quality of life. PubMed indexes it as a clinical and controlled clinical trial, but the abstract gives no denominator, allocation, comparator results, route, regimen, attrition, effect estimates, uncertainty, or adverse-event data.

Participants / model: Elderly patients with stage III rectal or colon cancer; denominator not stated in the abstract
Treatment: Vilon added to surgery, radiotherapy, and chemotherapy; regimen not stated
Study design: Russian-language controlled-trial-indexed report with preliminary conclusions and insufficient methods or results

Read the original source

Mouse tumors · earlier and multiple tumors reported

Animal carcinogenesis study

Anisimov VN et al. Bulletin of Experimental Biology and Medicine, 2001.

In HER2/neu transgenic mice, Vilon was associated with earlier tumor appearance and more multiple mammary tumors. The model cannot quantify human cancer risk; its direction was adverse.

Participants / model: HER2/neu transgenic mice
Treatment: Vilon
Study design: Animal carcinogenesis study

Read the original source

Animal tumors · favorable finding in another model

Animal study

Anisimov VN et al. Russian experimental oncology research.

A different animal experiment reported a favorable tumor-related finding after Vilon. Differences in model, timing, and endpoint prevent combining it into a general anticancer claim.

Participants / model: Experimental animal tumor model
Treatment: Vilon
Study design: Animal tumor study

Read the original source

ClinicalTrials.gov · no relevant intervention trial

Trial registrations

ClinicalTrials.gov.

ClinicalTrials.gov lists no exact-name Vilon intervention study. Older Russian-language reports without matching registrations remain separate evidence.

Read the original source

Why is Vilon in D tier?

The D grade reflects human reports that omit group sizes, treatment allocation, exposure, comparator results, and quantitative effects, plus unresolved safety.